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background:  Timely reperfusion after STEMI improves survival. Guidelines recommend primary percutaneous coronary intervention 
(PPCI) within 90 min of presentation to a PCI capable hospital. The alternative is fibrinolytic therapy within 30 min of presentation.
methods:  We identified STEMI patients receiving fibrinolytic or PPCI therapy at 229 hospitals participating in the Get With The Guidelines-
Coronary Artery Disease (GWTG-CAD) database (January 2003-December 2008). We examined temporal trends in the frequency of use 
of reperfusion therapies, timeliness of reperfusion and in-hospital mortality. We also assessed predictors of use of fibrinolytic therapy and 
compliance with performance measures (PM). Defect-free care was defined as 100% compliance with all PMs.
Results:  Of 29,190 STEMI patients identified, 2,441 (8.4%) received fibrinolytic therapy. Overall, 38.2% patients achieved DTN <30 min 
and 54.8% achieved door-to-balloon (DTB) <90 min. In contradistinction to PPCI, fibrinolytic therapy use decreased from 20.5% in 2003 
to 3.7% in 2008 (p<0.0001). During this period, door-to-needle (DTN) time increased (median, 36 to 60 minutes; p=0.005) while door-to-
balloon (DTB) time decreased (median, 94 to 64 minutes; p<0.0001). In-hospital mortality after fibrinolytic therapy for STEMI (average 
4.6%) was higher than that of PPCI (average 3.3%) during most time periods, and did not change significantly over time. Independent 
predictors of fibrinolytic use included: off-hour presentation, prior CABG, history of CAD, smoking and no hyperlipidemia. Although defect-
free care increased from 2003 to 2008 in patients receiving fibrinolytic therapy (74 to 91%, p<0.0001), these patients were overall less 
likely to receive defect-free care compared to PPCI patients (81% vs. 90%, p<0.0001).
conclusion:  Use of fibrinolytic therapy for STEMI decreased from 2003 to 2008 as the use of PPCI increased. Despite improvement 
in DTB time and defect-free care, worsening in DTN time was noted over the study period. In-hospital mortality among STEMI patients 
receiving fibrinolytic therapy remained unchanged over time and higher than that after PPCI.
